Clinical trials: Candidiasis, Oral
Oral Fungal Infection
Molecular Characterization of Candida Auris
Candida auris is emerging fungal opportunistic pathogen in developing countries. Much studies has been conducted on Candida albicans. there was a dire need to investigate this alarming threat.
- Trial name
- OC (NCT04121871)
- Testing
- No intervention
- Where
- 2 sites in Pakistan
- Volunteers
- 384 people
- Sponsor
- Islamia University of Bahawalpur
Oral Candida, Breastfeeding
Oral Candida in Infants and Dietary Type
This is an observational, non-randomised trial to evaluate the effect of dietary type on infants oral candida colonization the investigators evaluated 90 infants in 1-24 months (45 breastfeeding and 45 bottle feeding infants) who…
- Conditions
- Oral Candida, Breastfeeding, Bottle Feeding
- Trial name
- NCT01438983
- Where
- Iran
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shahid Sadoughi University of Medical Sciences and Health Services
Pneumonia, Pneumocystis Carinii, HIV Infections
Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)
To determine which of 2 doses of dapsone is effective prophylaxis for Pneumocystis carinii pneumonia (PCP) in patients with oral thrush or hairy leukoplakia and less than 400 CD4 lymphocytes per mm3.
- Trial name
- NCT00002043
- Testing
- Dapsone
- Where
- United States
- Sponsor
- Jacobus Pharmaceutical
Candidiasis, Candidemia
Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection
In this study we will measure the concentration of the drug called voriconazole which is used to fight infections caused by fungus in children who usually are cancer patients and have their immune system down.
- Trial name
- NCT00739934
- Testing
- voriconazole (Vfend)
- Where
- 14 sites in United States
- Volunteers
- 40 people
- Sponsor
- Pfizer
Newborns, Oral Hygiene
Effect of Oral Hygienization in Newborn on Candida Spp Colonization
Oral hygiene is one of the most accessible and well-known strategies for the prevention of dental caries. The benefits of this practice after tooth eruption are well established in the literature.
- Conditions
- Newborns, Oral Hygiene, Candidiasis, Oral, Behavior
- Trial name
- NCT04410250
- Testing
- oral hygiene
- Where
- Brazil
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Federal University of the Valleys of Jequitinhonha and Mucuri
Vulvovaginitis, Candidal, Vulvovaginal Candidiasis
Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.
- Conditions
- Vulvovaginitis, Candidal, Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
- Trial name
- NCT05908682
- Testing
- Non-interventional study
- Where
- India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Candidiasis, Esophageal, HIV Infections
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis.
- Trial name
- NCT00002041
- Testing
- Amphotericin B
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Candida Vulvovaginitis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
- Trial name
- NCT03734991
- Testing
- Ibrexafungerp
- Where
- 25 sites in United States
- Volunteers
- 376 people
- Sponsor
- Scynexis, Inc.
Candidiasis, Oral, HIV Infections
The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients
To evaluate the safety and effectiveness of Peridex (an oral rinse containing chlorhexidine gluconate) for preventing the occurrence of clinically-evident microbiologically-documented oral candidiasis in HIV-positive patients…
- Trial name
- NCT00002431
- Testing
- Chlorhexidine gluconate
- Where
- 5 sites in United States
- Sponsor
- Procter and Gamble
Candidiasis, Oral, HIV Infections
A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush
The purpose of this study is to determine whether it is better to treat patients with fluconazole on a continuous basis to prevent thrush (yeast infection in the mouth) from coming back or to wait and treat each episode of…
- Trial name
- NCT00000951
- Testing
- Fluconazole
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 948 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Candidiasis, Oral, HIV Infections
A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or IV, CDC classification)
- Trial name
- NCT00002293
- Testing
- Nystatin
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
Candidiasis, Oral
A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis
In resource constrained societies and where HIV is a problem, oral thrush causes significant morbidity. In adults, ketoconazole is used and sometimes oral nystatin.
- Trial name
- NCT00128323
- Testing
- Gentian violet 1% solution, Gentian violet 0.00165% solution, Nystatin solution
- Where
- Malawi
- Volunteers
- 558 people
- Sponsor
- Kamuzu University of Health Sciences
Recurrent Vulvovaginal Candidiasis
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Recurrent vulvovaginal candidiasis (RVVC), also known as recurrent yeast infections, is defined as at least 3 episodes of acute VVC in the past 12 months.
- Trial name
- VIOLET (NCT03562156)
- Testing
- Oteseconazole (VT-1161)
- Where
- 25 sites in United States
- Volunteers
- 438 people
- Sponsor
- Mycovia Pharmaceuticals Inc.
Candidiasis, Esophageal, HIV Infections
A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
To compare the safety, tolerance, and effectiveness of fluconazole and ketoconazole in the treatment of candidal esophagitis in immunocompromised patients.
- Trial name
- NCT00002304
- Testing
- Ketoconazole, Fluconazole
- Where
- 42 sites in United States, Canada
- Sponsor
- Pfizer
Candidiasis, Esophageal, HIV Infections
A Study of Fluconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
To determine the safety, toleration, and efficacy of fluconazole oral suspension in the treatment of esophageal candidiasis in immunocompromised patients, including those with AIDS.
- Trial name
- NCT00002339
- Testing
- Fluconazole
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Pfizer
Recurrent Vulvovaginal Candidiasis
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older…
- Trial name
- CANDLE (NCT04029116)
- Testing
- Fluconazole Tablet, IBREXAFUNGERP
- Where
- 25 sites in United States
- Volunteers
- 440 people
- Sponsor
- Scynexis, Inc.
Candida Vulvovaginitis
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.
- Trial name
- Vanish 306 (NCT03987620)
- Testing
- Ibrexafungerp
- Where
- 41 sites in United States, Bulgaria
- Volunteers
- 455 people
- Sponsor
- Scynexis, Inc.
Candidiasis, Oral, HIV Infections
A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole
To assess response and toxicity in patients with fluconazole-resistant oral candidiasis ( thrush ) when given initial induction with amphotericin B oral suspension.
- Trial name
- NCT00001065
- Testing
- Amphotericin B
- Where
- 32 sites in United States, Puerto Rico and 1 more
- Volunteers
- 70 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Candidiasis, Oral, Eating Disorders
The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection
The main objectives of this study are: 1) to determine whether various levels of severity of oral candidiasis (thrush) in the child are associated with different levels of speech production, feeding skills, and self-concept, and…
- Conditions
- Candidiasis, Oral, Eating Disorders, HIV Infections, Speech Disorders
- Trial name
- NCT00001448
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections, Candidiasis, Oral
Oral Manifestations of Human Immunodeficiency Virus Infection in High Risk Groups
OBJECTIVES: I. Evaluate the development of oral manifestations of human immunodeficiency virus infection in relationship to the onset of immunologic alterations and systemic symptoms in different risk groups: gay/bisexual men…
- Trial name
- NCT00004781
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)